Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
None of the nine patients who received the vaccine after surgery experienced recurrence over three years.
During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which combination therapy to use for a patient with metastatic renal cell carcinoma.
Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma therapy.
Metabolic dysregulation in the development of clear cell renal cell carcinoma (ccRCC) remains to be understood. Here the authors identify that a carnitine synthesis enzyme BBOX1, which inhibits TBK1-mTORC1 signaling and glycolysis, is often lost in ccRCC.
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma.
... renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI) and/or tyrosine kinase inhibitors (TKI), investigators report. Shahrokh ...
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary Cancers Symposium later this week in San Francisco, California.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.